{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"1.4"},{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"1.3","upperLimit":"NA","value":"1.5"},{"comment":"Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"1.4","upperLimit":"NA","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Time to progression was defined as the time from start date of treatment to the date of the first documentation of PD. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions. 95% CI was based on Brookmeyer and Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 2\\*10\\^8 plaque forming unit (PFU) once weekly for 4 weeks as an intravenous (IV) push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG000","title":"Part 1A PF-07263689 2*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 6\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG001","title":"Part 1A PF-07263689 6*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 20\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG002","title":"Part 1A PF-07263689 20*10^8PFU"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all enrolled participants. Data is not reported for Part 1b as no participants were enrolled and data was not collected.","reportingStatus":"POSTED","timeFrame":"From start date of treatment to the date of first documentation of PD (up to maximum follow-up of 10.45 months)","title":"Part 1: Time to Progression","type":"SECONDARY","unitOfMeasure":"Months"}